Domainex is a Cambridge-based UK biotech company, which operates a hybrid business model. This model enables revenue generation through its pharmaceutical outsourcing for contract manufacturing, in parallel with the development of an internal drug discovery pipeline. This model significantly reduces the investment requirements, when compared with biotech companies more broadly, and enables a significant in-house capability to be maintained.
Domainex's drug discovery services business was established in 2001 and since that time has continued to expand to serve a wider range of clients across the world, including UCB, FORMA Therapeutics, St George's University, The Institute of Cancer Research and Auspherix. It has a superb success record for a company of 35-40 people, delivering on average one candidate drug every year for the past six.
More information regarding Domainex's drug discovery services can be found by following the relevant links, including its platform technologies, medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering.
Details of Domainex's drug discovery pipeline can be found by following the links below: